Liver Transplantation and Metabolic Dysfunction Associated Steatotic Liver Disease Is Associated with Markers of Metabolic Risk and Inflammation

作者：Rehan Razzaq, Madison Nguyen, Margery A. Connelly, Alok Baral, Hiba Khan, Shreya Garg, Audrey Ang, A Hyeon Kim, Geneva Roache, Kavish R. Patidar, Idris Yakubu, Irina Shalaurova, Stephan J. L. Bakker, Robin P. F. Dullaart, Vinay Kumaran, Anh Tuan Bui, Vaishali Patel, Mohammad Shadab Siddiqui · 发表于：Digestive Diseases and Sciences · 年份：2025 · DOI：10.1007/s10620-025-09072-1 · 被引用次数：5 · 研究领域：Liver Disease Diagnosis and Treatment、Liver Disease and Transplantation、Nutrition and Health in Aging

BACKGROUND: Liver transplant (LT) recipients are at high risk of cardiometabolic disease and mortality. However, routinely employed clinical risk tools have sub-optimal diagnostic performance due to transplant related biological changes. Metabolic vulnerability index (MVX) is a serum-based composite biomarker comprised of nutritional risk [metabolic malnutrition index or MMX] and chronic inflammation [inflammatory vulnerability index or IVX]. MVX is a predictor of cardiovascular risk and all-cause mortality in the general population, however, the effect of LT on MVX is unknown. METHODS: and BMI-matched controls who were propensity matched for BMI. RESULTS: Compared to matched controls, LT recipients had significantly higher MVX (56.9 ± 10.1 vs. 45.8 ± 9.4 vs. 44.8 ± 9.3, p < 0.001), IVX [53.1 ± 12 vs. 39.3 ± 11.2 vs. 40.2 ± 10.9, p < 0.001), and MMX (58.7 ± 8.2 vs. 55.4 ± 6.5 vs. 53.1 ± 6.0, p < 0.001). No significant differences were noted in MVX in LT recipients who developed metabolic dysfunction associated steatotic liver disease (MASLD) after LT. In a multivariate analysis, MVX scores were positively associated with female gender, diabetes, serum AST and BMI, and negatively with dyslipidemia. CONCLUSION: LT is associated with a significant increase in MVX and its components, suggesting a heightened risk in LT recipients that is above that of the non-LT population. Future well designed prospective studies are required to calibrate MVX to clinical outcomes in LT patients.